Small molecule · Inhibitor of CDC2-like kinase 1 (CLK1), CDC2-like kinase 2 (CLK2) and CDC2-like kinase 4 (CLK4) · developed by BlossomHill Therapeutics
BH-30236 is an orally bioavailable macrocyclic ATP-competitive inhibitor of the CLK family kinases CLK1, CLK2 and CLK4. It blocks phosphorylation of serine/arginine-rich splicing factors, altering RNA splicing in tumor cells. It is being studied in leukemia and myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06501196 | Phase 1 | Leukemia | Recruiting | BLSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, AcuteMyelodysplastic SyndromesPreleukemiaRefractory Acute Myeloid Leukemia
Updated Oct 11, 2026. Something wrong or missing? Report it on the BLSM page.
See BLSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BLSM catalysts and pipeline →